Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

NCT04872582 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Nasopharyngeal Carcinoma
Chemotherapy Effect

Interventions

DRUG: PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab

Sponsor

XIANG YANQUN